Fractyl Health Inc. (GUTS) is a Medical/Dental Instruments company listed on NASDAQ. In the last 30 days Quantisnow tracked 11 wire items for GUTS, including 5 press releases and news items, 3 SEC filings and 1 market update. The most recent was published Nov 6, 2026.
Financial highlights
Full financials- Revenue, FY2025
- $0
- Revenue growth
- -100.0%
- Net income, FY2025
- -$140.95M
- Free cash flow, FY2025
- -$90.89M
- Cash
- $47.14M
For fiscal 2025 (ended Dec 31, 2025), from SEC filings. Not investment advice.
News · 26 weeks42+14%
2026-05-172026-11-08
Mix2090d
- Other7(35%)
- SEC Filings7(35%)
- Market3(15%)
- Insider2(10%)
- Earnings1(5%)
Activity · 52 weeks7945 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- INSIDERSEC Form 3 filed by new insider Wartell Michael J.3 - FRACTYL HEALTH, INC. (0001572616) (Issuer)
- SECFractyl Health Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - FRACTYL HEALTH, INC. (0001572616) (Filer)
- PRFractyl Health to Report Third Quarter 2026 Financial Results and Provide Business Updates on November 12, 2026BURLINGTON, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced that it will report financial results for the third quarter 2026 and provide business updates on Thursday, November 12, 2026, at 4:30 p.m. ET. A live webcast of the conference call and presentation can be accessed in the "Events" section of Fractyl Health’s website at http://ir.fractyl.com. The webcast will be archived and available for replay following the live event. To enhance engagement with the company's shareholder base, Frac
- PRFractyl Health Strengthens Revita Patent Portfolio as It Advances Toward FDA Submission and Potential CommercializationPatent milestones build on positive REMAIN-1 six-month pivotal results and patient research supporting interest in a one-time procedure for post-GLP-1 weight maintenanceNew catheter patent provides protection extending to 2042; broader portfolio includes issued duodenum treatment-method claims not limited to any specific energy modalityFractyl’s IP portfolio includes 39 granted U.S. patents, approximately 40 pending U.S. applications and more than 50 issued international patents BURLINGTON, Mass., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obe
- PRFractyl Health Announces Market Research Highlighting Substantial Patient Interest in a One-Time Procedural Approach to Post-GLP-1 Weight MaintenanceCompany estimates approximately one million U.S. patients each month discontinue GLP-1 medications and face the risk of weight regainOne-third of surveyed GLP-1 users expressed a preference for an endoscopic procedure over continued GLP-1 medicationA one-time procedure and freedom from daily or weekly medication were the most frequently selected positive attributes, supporting commercial planning for Revita BURLINGTON, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced findings from company-spo
- SECSEC Form 8-K filed by Fractyl Health Inc.8-K - FRACTYL HEALTH, INC. (0001572616) (Filer)
- PRFractyl Health Sharpens Focus on Revita Following Positive Pivotal Results, Advancing Toward Planned FDA De Novo Submission in Post-GLP-1 Weight MaintenanceFollowing positive topline six-month REMAIN-1 pivotal results, Revita advancing toward planned FDA De Novo submission in late Q4 2026 and anticipated 12-month pivotal data readout in Q1 2027 Workforce reduction aligns organization behind Revita's near-term clinical and commercial opportunity Company discontinuing development of Rejuva candidates and seeking strategic alternatives to maximize the value of its Rejuva gene therapy program Cash runway extended into Q2 2027; quarterly operating cash burn expected to be reduced by ~50% to approximately $8 million by end of Q2 2027 BURLINGTON, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the Company or
- PRINVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Fractyl Health, Inc. to Contact Law FirmFractyl Health, Inc. (NASDAQ:GUTS) shareholders should email fletcher@fmoorelaw.comNEW YORK, Oct. 19, 2026 /PRNewswire/ -- What is the Investigation About?On January 29, 2026, before the market opened, Fractyl Health, Inc. announced six-month data from its REMAIN-1 Midpoint Cohort evaluating Revita for weight maintenance after discontinuation of GLP-1 therapy. Revita-treated patients experienced 4.5% weight regain, compared with 7.5% in the sham-treatment group. The Company also stated that the cohort was not designed to be sufficiently powered for efficacy analysis. During an investor call that same day, management disclosed t
- NEWSGUTS UPCOMING DEADLINE: Levi & Korsinsky Alerts Fractyl Health, Inc. Stockholders of Securities Class Action - Contact the FirmNEW YORK CITY, NY / ACCESS Newswire / October 16, 2026 / Levi & Korsinsky, LLP alerts investors in Fractyl Health, Inc. (NASDAQ:GUTS) that a securities class action has been filed on behalf of shareholders who purchased securities between January 13, 2025 and January 29, 2026. Find out if you may qualify to recover losses. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or ☎(212) 363-7500.GUTS closed at $1.83 on January 28, 2026. Two sessions later it closed at $0.46, a cumulative decline of $1.37 per share, or approximately 74.86%. To be considered for lead plaintiff, investors must file by October 20, 2026.How the Market Repriced GUTS Over Two SessionsOn January 29, 20
- SECSEC Form 8-K filed by Fractyl Health Inc.8-K - FRACTYL HEALTH, INC. (0001572616) (Filer)
- PRFractyl Health's Revita Meets Six-Month Co-Primary Endpoint in Ongoing REMAIN-1 Pivotal Study, With Highly Statistically Significant Reduction in Weight Regain After GLP-1 DiscontinuationREMAIN-1 met its six-month co-primary endpoint with high statistical significance (p=0.0023; mITT population); demonstrated 80% retention of GLP-1 induced weight loss vs 67% for sham 32% of Revita® participants in primary analysis population (mITT) were either weight stable or had further weight loss at 6-months post GLP-1 discontinuation vs 18% for sham (post hoc; nominal p=0.020) Post hoc analyses demonstrated that patients receiving a single complete duodenal ablation with Revita (>=20 cm length) regained 3.8% total body weight vs 8.2% in sham, reflecting a 53% reduction in weight regain between Month 1 and Month 6 (nominal p=0.003) Revita has been generally well-tolerated with no devi
- NEWSGUTS Shareholder Alert: Fractyl Health, Inc. Securities Class Action Lawsuit - Investors Should Contact Levi & KorsinskyNEW YORK CITY, NY / ACCESS Newswire / October 9, 2026 / Levi & Korsinsky, LLP notifies investors in Fractyl Health, Inc. (NASDAQ:GUTS) that a securities class action has been filed on behalf of shareholders who purchased securities between January 13, 2025 and January 29, 2026. Submit your information now. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or ☎(212) 363-7500.GUTS shares fell from a Class Period high of $1.83 on January 28, 2026 to $0.46 on January 30, 2026, a cumulative decline of $1.37 per share, or 74.86%. The lead plaintiff deadline is October 20, 2026.What Fractyl's SEC Filings DisclosedQuarterly and annual reports filed during the Class Period describe
- NEWSGUTS DEADLINE: Levi & Korsinsky Reminds Fractyl Health, Inc. Investors of Upcoming Securities Class Action DeadlineNEW YORK CITY, NY / ACCESS Newswire / October 2, 2026 / Levi & Korsinsky, LLP reminds purchasers of Fractyl Health, Inc. (NASDAQ:GUTS) securities of a pending securities class action brought on behalf of investors who purchased shares between January 13, 2025 and January 29, 2026. See if you could be eligible to recover. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or ☎(212) 363-7500.GUTS shares closed at $0.46 on January 30, 2026, down from a Class Period price of $1.83 on January 28, 2026, a cumulative decline of $1.37 per share, or 74.86%. Investors have until October 20, 2026 to seek lead plaintiff status.Chronology of Material EventsJanuary 13, 2025: Fractyl anno
- SECFractyl Health Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - FRACTYL HEALTH, INC. (0001572616) (Filer)
- SECFractyl Health Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - FRACTYL HEALTH, INC. (0001572616) (Filer)
- INSIDERDirector Bradley William bought $39,903 worth of shares (64,516 units at $0.62), increasing direct ownership by 76% to 149,138 units (SEC Form 4)4 - FRACTYL HEALTH, INC. (0001572616) (Issuer)
- SECFractyl Health Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - FRACTYL HEALTH, INC. (0001572616) (Filer)
- PRFractyl Health to Participate in Upcoming September Investor ConferencesBURLINGTON, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the Company or Fractyl), a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced that Harith Rajagopalan, M.D., Ph.D., Co-Founder and Chief Executive Officer of the Company, will be participating in the following upcoming investor conferences: H.C. Wainwright 28th Annual Global Investment ConferenceFormat: On-demand presentation and one-on-one meetingsPresentation available beginning Friday, September 11, 2026 at 7:00 AM ETOne-on-one meetings: Tuesday, September 15, 2026 Morgan Stanley 24th Annual Global Hea
- SECSEC Form DEF 14A filed by Fractyl Health Inc.DEF 14A - FRACTYL HEALTH, INC. (0001572616) (Filer)
- PRFractyl Health to Host Virtual Commercial Strategy Day on Tuesday, September 1, 2026: The Potential Path to Commercializing Revita®, a Procedural Therapy for Post-GLP-1 Weight MaintenanceBURLINGTON, Mass., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the Company or Fractyl), a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced that it will host a virtual Commercial Strategy Day on Tuesday, September 1, 2026 at 11:00 AM ET to discuss the potential commercial opportunity and go-to-market strategy for Revita®. To register, click here. The event follows the Company’s positive one-year randomized data from the REMAIN-1 Midpoint Cohort, which showed weight maintenance one year after a single Revita procedure. The treatment effect was greatest in a pre-specified
- SECSEC Form 10-Q filed by Fractyl Health Inc.10-Q - FRACTYL HEALTH, INC. (0001572616) (Filer)
- SECFractyl Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - FRACTYL HEALTH, INC. (0001572616) (Filer)
- PRFractyl Health Reports Second Quarter 2026 Financial Results and Business UpdatesOne-year REMAIN-1 Midpoint Cohort data show Revita patients maintained up to 84% of prior GLP-1-induced weight loss versus 46% with sham in patients receiving complete duodenal ablations — the first randomized evidence of durable, drug-free weight maintenance One-year open-label REVEAL-1 Cohort data provide real-world evidence of durable weight maintenance, with patients maintaining approximately 78% of their prior GLP-1-induced weight loss after a single Revita procedure REMAIN-1 Pivotal Cohort topline data on track for early Q4 2026, paving the way for potential FDA De Novo submission in post-GLP-1 weight maintenance in late Q4 2026 Cash runway guidance into early 2027, beyond anticipat
- PRFractyl Health to Report Second Quarter 2026 Financial Results and Provide Business Updates on August 10, 2026BURLINGTON, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced that it will report financial results for the second quarter 2026 and provide business updates on Monday, August 10, 2026, at 4:30 p.m. ET. A live webcast of the conference call and presentation can be accessed in the "Events" section of Fractyl Health’s website at http://ir.fractyl.com. The webcast will be archived and available for replay following the live event. About Fractyl Health Fractyl Health is a clinical-stage m
- PRFractyl Health to Participate in Upcoming Investor EventsBURLINGTON, Mass., July 22, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced that Harith Rajagopalan, M.D., Ph.D., Co-Founder and Chief Executive Officer of the Company, will be participating in the following upcoming investor conferences: BTIG Virtual Biotechnology ConferenceFormat: One-on-one meetingsDates: July 28 – 29, 2026 Needham & Company MedTech & Diagnostics 1x1 ConferenceFormat: One-on-one meetingsDates: August 10 – 11, 2026 Canaccord Genuity 46th Annual Growth ConferenceFormat: Fireside chat and
GUTS FAQ
10 questionsWhat is the latest news on GUTS?
In the last 30 days Quantisnow tracked 11 wire items for GUTS: 5 press releases and news items, 3 SEC filings, 1 market update and 1 earnings update. The most recent was published on November 6, 2026.What is GUTS revenue?
Fractyl Health Inc. (GUTS) reported $0 of revenue for fiscal 2025 (ended Dec 31, 2025). That is down 100.0% from the year before.Is GUTS profitable?
No. Fractyl Health Inc. reported a net loss of $140.95M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does GUTS have?
Fractyl Health Inc. reported $47.14M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does GUTS stock trade?
Fractyl Health Inc. (GUTS) is listed on NASDAQ.What sector and industry is GUTS in?
Fractyl Health Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did Fractyl Health Inc. go public?
Fractyl Health Inc. (GUTS) completed its IPO in 2024.What are analysts saying about GUTS?
Across the last 6 analyst actions on Fractyl Health Inc., there were 0 upgrades and 1 downgrade. The most recent action was from Morgan Stanley: Equal-Weight with a $2.00 price target on 2026-01-30.What companies are similar to GUTS?
Notable peers in the same industry include SYK (Stryker Corporation), MDT (Medtronic plc.), BSX (Boston Scientific Corporation), INSP (Inspire Medical Systems Inc.), ISRG (Intuitive Surgical Inc.). Compare GUTS side-by-side with any of them on Quantisnow.How can I track GUTS on Quantisnow?
Quantisnow aggregates Fractyl Health Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GUTS to receive live email and push alerts on every new disclosure.